Literature DB >> 24716820

Use of an insulin bolus advisor facilitates earlier and more frequent changes in insulin therapy parameters in suboptimally controlled patients with diabetes treated with multiple daily insulin injection therapy: results of the ABACUS trial.

David A Cavan1, Ralph Ziegler, Iain Cranston, Katharine Barnard, Jacqueline Ryder, Claudia Vogel, Christopher G Parkin, Walter Koehler, Iris Vesper, Bettina Petersen, Matthias A Schweitzer, Robin S Wagner.   

Abstract

BACKGROUND: We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with multiple daily insulin injection (MDI) therapy. SUBJECTS AND METHODS: The Automated Bolus Advisor Control and Usability Study (ABACUS) trial, a 26-week, prospective, randomized, controlled, multinational study that enrolled 218 type 1 and type 2 diabetes patients, demonstrated that use of an automated insulin bolus advisor helps improve glycemic control in suboptimally controlled, MDI-treated patients. Patient data were assessed to determine when and how often changes in insulin parameter settings occurred during the study. Patient meters were downloaded to determine blood glucose monitoring frequency.
RESULTS: One hundred ninety-three patients completed the study: 93 control arm (CNL) and 100 intervention (experimental) arm (EXP). Significantly more EXP (47.5%) than CNL (30.7%) patients received one or more changes in their insulin sensitivity factor (ISF) settings during the study (P=0.0191). Changes in ISF settings occurred earlier and more frequently in EXP than CNL patients throughout the study. A similar trend was seen in changes in insulin-to-carbohydrate ratios. There were no differences in daily self-monitoring of blood glucose frequency [mean (SD)] between CNL and EXP patients: 4.7 (1.5) versus 4.6 (1.3) (P=0.4085).
CONCLUSIONS: Use of an automated bolus advisor was associated with earlier, more frequent changes in key insulin parameters, which may have contributed to subsequent improvements in glycemic control but without increased glucose test strip utilization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24716820     DOI: 10.1089/dia.2013.0280

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  7 in total

Review 1.  Boluses in Insulin Therapy.

Authors:  Ralph Ziegler; Guido Freckmann; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-07-10

2.  Self-Management Behaviors in Adults on Insulin Pump Therapy.

Authors:  Danielle Groat; Maria Adela Grando; Hiral Soni; Bithika Thompson; Mary Boyle; Marilyn Bailey; Curtiss B Cook
Journal:  J Diabetes Sci Technol       Date:  2016-09-25

Review 3.  [New technologies in diabetology. How far are we from a closed loop?].

Authors:  G Freckmann
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

4.  Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy: Lessons Learned From the Automated Bolus Advisor Control and Usability Study (ABACUS).

Authors:  Christopher G Parkin; Katharine Barnard; Deborah A Hinnen
Journal:  J Diabetes Sci Technol       Date:  2015-03-20

5.  Unknown Safety and Efficacy of Smartphone Bolus Calculator Apps Puts Patients at Risk for Severe Adverse Outcomes.

Authors:  Irl B Hirsch; Christopher G Parkin
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

Review 6.  Improving pregnancy outcomes in women with diabetes mellitus: modern management.

Authors:  Lene Ringholm; Peter Damm; Elisabeth R Mathiesen
Journal:  Nat Rev Endocrinol       Date:  2019-07       Impact factor: 43.330

7.  Bolus Calculator Reduces Hypoglycemia in the Short Term and Fear of Hypoglycemia in the Long Term in Subjects with Type 1 Diabetes (CBMDI Study).

Authors:  María Del Rosario Vallejo Mora; Mónica Carreira; María Teresa Anarte; Francisca Linares; Gabriel Olveira; Stella González Romero
Journal:  Diabetes Technol Ther       Date:  2017-06-08       Impact factor: 6.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.